Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 66 cents per share.
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Arrivent Biopharma Inc is $39.00, above its last closing price of $21.30.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.78 | -0.78 | -0.61 | Beat | 21.5 |
Sep. 30 2024 | -0.72 | -1.00 | -0.61 | Beat | 39.1 |
Jun. 30 2024 | -0.65 | -0.64 | -0.65 | Missed | -1 |
Mar. 31 2024 | -1.09 | -1.10 | -0.70 | Beat | 36.2 |
| |||||
|
This summary was machine generated May 5 at 11:33 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。